Why FDA Said No to a Melanoma Drug - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

  • By

  • Arthur Allen

  • May 15, 2026

  • 9 min

Share

Original Source(s)

Why FDA Said No to a Melanoma Drug

  • by Arthur Allen

  • May 15, 2026

Related Content

Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis

Topical Recombinant Collagen Following Fractional Radio Frequency Microneedling for Nonsurgical Facelift: Case Report

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2